Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4Thoracic 1

Conditions

Multiple Myeloma 32Recurrence 14Leukemia, Myeloid, Acute 14Hodgkin Disease 12Lymphoma 11Neoplasms 10Breast Neoplasms 9Myelodysplastic Syndromes 8Lymphoma, Non-Hodgkin 8Lymphoma, Large B-Cell, Diffuse 8Prostatic Neoplasms 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia 7Carcinoma, Non-Small-Cell Lung 7Lymphoma, T-Cell, Cutaneous 6Sezary Syndrome 5Neoplasms, Plasma Cell 5Mycosis Fungoides 5Lymphoma, Mantle-Cell 5Leukemia, Lymphocytic, Chronic, B-Cell 5Glioma 5Waldenstrom Macroglobulinemia 4Neoplasm Metastasis 4Melanoma 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, Extranodal NK-T-Cell 4Immunoblastic Lymphadenopathy 4Diffuse Intrinsic Pontine Glioma 4Advanced Solid Tumors 4Primary Myelofibrosis 3

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 135Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 67fludarabine phosphate 61Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Cisplatin 36CTLA-4 Antigen 36Carboplatin 35cobimetinib 34Specimen Handling 34Magnetic Resonance Spectroscopy 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Melanoma × Panobinostat × Clear all
NCT02032810 2023-01-20

Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
17 enrolled 12 charts
Dermatologic

Melanoma, Skin Neoplasms

NCT03982134 2019-10-04

PDR001 + Panobinostat for Melanoma and NSCLC

University of Iowa

Phase 1 Withdrawn
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT00925132 2017-07-02

Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat

University of Iowa

Phase 1/2 Terminated
39 enrolled 8 charts
Dermatologic

Melanoma, Neoplasm Metastasis

NCT01065467 2017-03-28

Panobinostat (LBH589) in Patients With Metastatic Melanoma

Dana-Farber Cancer Institute

Phase 1 Completed
16 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡